Accenture has taken a major step into the future of life sciences, investing in Ryght AI, a platform that modernizes how clinical research is designed and executed. The deal, made through Accenture Ventures, aims to help life sciences and clinical research companies bring new treatments to patients faster by combining agentic AI with enterprise technology solutions.
As clinical trials grow more complex, delays in site selection and patient enrollment are increasingly common, driving up drug development costs. Manual site selection alone can add weeks—or even months—to studies, creating bottlenecks that stall the rollout of promising therapies.
Ryght AI tackles these hurdles with its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites. The platform captures historical performance, patient demographics, and operational data in real-time, helping sponsors and contract research organizations identify sites that meet regulations and protocols, forecast enrollment, and streamline site activation workflows.
The investment will merge Accenture’s industry, technology, and data-engineering expertise with Ryght AI’s advanced agentic AI platform to accelerate the three critical steps in drug development: trial feasibility, site selection, and patient recruitment.
“Generative and agentic AI are transforming the foundation of clinical research,” said Petra Jantzer, senior managing director and global lead of Life Sciences, Accenture. “With our investment in Ryght AI, we’re giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently and with greater precision.”
Simon Arkell, CEO of Ryght AI, added, “This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched and managed—accelerating the journey from discovery to treatment.”
Terms of the investment were not disclosed. Ryght AI joins a growing portfolio of innovative biotech startups backed by Accenture Ventures, including 1910 Genetics, Turbine, and Earli, all leveraging technology to speed up clinical trials and drug therapy.
